Targeting protein homeostasis in sporadic inclusion body myositis

Co-induction of the heat shock response ameliorates disease progression in a mouse model of human spinal and bulbar muscular atrophy: implications for therapy

(2013) Bilal Malik et al.   BRAIN

Update in inclusion body myositis

(2013) Pedro Machado et al.   CURRENT OPINION IN RHEUMATOLOGY

Longitudinal observational study of sporadic inclusion body myositis: Implications for clinical trials

(2013) A. Cortese et al.   NEUROMUSCULAR DISORDERS

Update on Treatment of Inclusion Body Myositis

(2013) Maren Breithaupt et al.   Current Rheumatology Reports

Nitric oxide stress in sporadic inclusion body myositis muscle fibres: inhibition of inducible nitric oxide synthase prevents interleukin-1β-induced accumulation of β-amyloid and cell death

(2012) Jens Schmidt et al.   BRAIN

Inclusion Body Myositis

(2012) Mazen M. Dimachkie et al.   Current Neurology and Neuroscience Reports

Pathogenesis and therapies of immune-mediated myopathies

(2011) Marinos C. Dalakas   AUTOIMMUNITY REVIEWS

Circulating Heat Shock Protein 70 in Health, Aging and Disease

(2011) Rose Njemini et al.   BMC IMMUNOLOGY

A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities

(2011) Fieke M. Cox et al.   BRAIN

Long-term observational study of sporadic inclusion body myositis

(2011) O. Benveniste et al.   BRAIN

Inclusion body myositis

(2011) Steven A. Greenberg   CURRENT OPINION IN RHEUMATOLOGY

Transgenic mice expressing mutant forms VCP/p97 recapitulate the full spectrum of IBMPFD including degeneration in muscle, brain and bone

(2010) Sara K. Custer et al.   HUMAN MOLECULAR GENETICS

The relationship between heat shock protein 72 expression in skeletal muscle and insulin sensitivity is dependent on adiposity

(2010) Darren C. Henstridge et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Theories of the Pathogenesis of Inclusion Body Myositis

(2010) Steven A. Greenberg   Current Rheumatology Reports

p62/SQSTM1 is overexpressed and prominently accumulated in inclusions of sporadic inclusion-body myositis muscle fibers, and can help differentiating it from polymyositis and dermatomyositis

(2009) Anna Nogalska et al.   ACTA NEUROPATHOLOGICA

Interplay between protein homeostasis networks in protein aggregation and proteotoxicity

(2009) Peter M. Douglas et al.   BIOPOLYMERS

Arimoclomol: a potential therapy under development for ALS

(2009) Veena Lanka et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Evaluation and treatment of inflammatory myopathies

(2009) A A Amato et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis

(2009) Mohammad Salajegheh et al.   MUSCLE & NERVE

The Exercise-Induced Stress Response of Skeletal Muscle, with Specific Emphasis on Humans

(2009) James P. Morton et al.   SPORTS MEDICINE

Interrelation of inflammation and APP in sIBM: IL-1β induces accumulation of β-amyloid in skeletal muscle

(2008) Jens Schmidt et al.   BRAIN

Caspase-cleaved TAR DNA-binding protein-43 is a major pathological finding in Alzheimer's disease

(2008) Troy T. Rohn   BRAIN RESEARCH

Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis

(2008) Merrilee Needham et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1G93A mouse model of ALS

(2008) Bernadett Kalmar et al.   JOURNAL OF NEUROCHEMISTRY

TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia

(2008) C C Weihl et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Inclusion body myositis functional rating scale: A reliable and valid measure of disease severity

(2008) C.E. Jackson et al.   MUSCLE & NERVE

Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis

(2008) Merit E. Cudkowicz et al.   MUSCLE & NERVE